Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	RNA polymerase I general transcription initiation factor activity	UBTFL6 UBTF UBTFL1 TAF1	1.93e-08	9	72	4	GO:0001181
GeneOntologyMolecularFunction	core promoter sequence-specific DNA binding	UBTFL6 UBTF UBTFL1 TAF1 RFX7 KCNIP3	4.48e-08	55	72	6	GO:0001046
GeneOntologyMolecularFunction	RNA polymerase I core promoter sequence-specific DNA binding	UBTFL6 UBTF UBTFL1	7.26e-06	11	72	3	GO:0001164
GeneOntologyMolecularFunction	RNA polymerase I transcription regulatory region sequence-specific DNA binding	UBTFL6 UBTF UBTFL1	1.25e-05	13	72	3	GO:0001163
GeneOntologyMolecularFunction	general transcription initiation factor activity	UBTFL6 UBTF UBTFL1 TAF1	1.06e-04	68	72	4	GO:0140223
GeneOntologyMolecularFunction	phosphotransferase activity, alcohol group as acceptor	JAK1 JAK2 NRBP2 PNCK DCLK2 PRKDC TAF1 PAPSS1 ALPK2 STK25	2.19e-04	709	72	10	GO:0016773
GeneOntologyMolecularFunction	protein kinase activity	JAK1 JAK2 NRBP2 PNCK DCLK2 PRKDC TAF1 ALPK2 STK25	2.96e-04	600	72	9	GO:0004672
GeneOntologyMolecularFunction	kinase activity	JAK1 JAK2 NRBP2 PNCK DCLK2 PRKDC TAF1 PAPSS1 ALPK2 STK25	3.98e-04	764	72	10	GO:0016301
GeneOntologyMolecularFunction	growth hormone receptor binding	JAK1 JAK2	5.66e-04	10	72	2	GO:0005131
GeneOntologyMolecularFunction	protein serine/threonine kinase activity	NRBP2 PNCK DCLK2 PRKDC TAF1 ALPK2 STK25	1.12e-03	446	72	7	GO:0004674
GeneOntologyBiologicalProcess	transcription initiation at RNA polymerase I promoter	UBTFL6 UBTF UBTFL1 TAF1	3.59e-07	18	70	4	GO:0006361
GeneOntologyBiologicalProcess	RNA polymerase I preinitiation complex assembly	UBTFL6 UBTF UBTFL1	6.06e-06	11	70	3	GO:0001188
Domain	FERM_central	JAK1 JAK2 FRMD4A TLN2	3.57e-05	49	71	4	IPR019748
Domain	FERM_domain	JAK1 JAK2 FRMD4A TLN2	3.57e-05	49	71	4	IPR000299
Domain	FERM_1	JAK1 JAK2 FRMD4A TLN2	3.87e-05	50	71	4	PS00660
Domain	FERM_2	JAK1 JAK2 FRMD4A TLN2	3.87e-05	50	71	4	PS00661
Domain	FERM_3	JAK1 JAK2 FRMD4A TLN2	3.87e-05	50	71	4	PS50057
Domain	Band_41_domain	JAK1 JAK2 FRMD4A TLN2	3.87e-05	50	71	4	IPR019749
Domain	B41	JAK1 JAK2 FRMD4A TLN2	3.87e-05	50	71	4	SM00295
Domain	HMG_BOX_2	UBTFL6 UBTF UBTFL1 TAF1	5.25e-05	54	71	4	PS50118
Domain	Ubiquitin-rel_dom	FRMD4A ARAP3 RASSF1 PPP1R13B TLN2 ASPSCR1	7.10e-05	184	71	6	IPR029071
Domain	Tyr_kinase_non-rcpt_Jak/Tyk2	JAK1 JAK2	8.51e-05	4	71	2	IPR016251
Domain	Laminin_aI	LAMA1 LAMA2	1.41e-04	5	71	2	IPR009254
Domain	Laminin_I	LAMA1 LAMA2	1.41e-04	5	71	2	PF06008
Domain	Laminin_II	LAMA1 LAMA2	1.41e-04	5	71	2	PF06009
Domain	Laminin_domII	LAMA1 LAMA2	1.41e-04	5	71	2	IPR010307
Domain	LAMININ_IVA	LAMA1 LAMA2	3.93e-04	8	71	2	PS51115
Domain	Laminin_B	LAMA1 LAMA2	3.93e-04	8	71	2	PF00052
Domain	LamB	LAMA1 LAMA2	3.93e-04	8	71	2	SM00281
Domain	Laminin_IV	LAMA1 LAMA2	3.93e-04	8	71	2	IPR000034
Domain	Laminin_G_1	LAMA1 LAMA2	7.66e-04	11	71	2	PF00054
Domain	Kinase-like_dom	JAK1 JAK2 NRBP2 PNCK DCLK2 PRKDC ALPK2 STK25	1.02e-03	542	71	8	IPR011009
Domain	HMG_box	UBTFL6 UBTF UBTFL1	1.08e-03	53	71	3	PF00505
Domain	OTU	OTUD4 TNFAIP3	1.08e-03	13	71	2	PF02338
Domain	Recoverin	KCNIP3 KCNIP2	1.08e-03	13	71	2	IPR028846
Domain	HMG	UBTFL6 UBTF UBTFL1	1.14e-03	54	71	3	SM00398
Domain	OTU	OTUD4 TNFAIP3	1.45e-03	15	71	2	PS50802
Domain	OTU_dom	OTUD4 TNFAIP3	1.45e-03	15	71	2	IPR003323
Domain	Laminin_N	LAMA1 LAMA2	1.65e-03	16	71	2	IPR008211
Domain	LAMININ_NTER	LAMA1 LAMA2	1.65e-03	16	71	2	PS51117
Domain	Laminin_N	LAMA1 LAMA2	1.65e-03	16	71	2	PF00055
Domain	LamNT	LAMA1 LAMA2	1.65e-03	16	71	2	SM00136
Domain	HMG_box_dom	UBTFL6 UBTF UBTFL1	1.94e-03	65	71	3	IPR009071
Domain	IGc2	NRCAM PSG9 MYPN ROBO2 ALPK2	2.00e-03	235	71	5	SM00408
Domain	Ig_sub2	NRCAM PSG9 MYPN ROBO2 ALPK2	2.00e-03	235	71	5	IPR003598
Domain	FERM_CS	FRMD4A TLN2	3.73e-03	24	71	2	IPR019747
Domain	IG	SEMA3D NRCAM PSG9 MYPN ROBO2 ALPK2	5.28e-03	421	71	6	SM00409
Domain	Ig_sub	SEMA3D NRCAM PSG9 MYPN ROBO2 ALPK2	5.28e-03	421	71	6	IPR003599
Domain	PH_dom-like	JAK1 JAK2 MAPK8IP1 FRMD4A ARAP3 TLN2	5.59e-03	426	71	6	IPR011993
Domain	EGF_LAM_2	LAMA1 LAMA2	5.79e-03	30	71	2	PS50027
Domain	EGF_LAM_1	LAMA1 LAMA2	5.79e-03	30	71	2	PS01248
Domain	Ig_I-set	NRCAM MYPN ROBO2 ALPK2	5.93e-03	190	71	4	IPR013098
Domain	I-set	NRCAM MYPN ROBO2 ALPK2	5.93e-03	190	71	4	PF07679
Domain	FERM_N	FRMD4A TLN2	6.97e-03	33	71	2	PF09379
Domain	FERM_N	FRMD4A TLN2	6.97e-03	33	71	2	IPR018979
Domain	EF-hand_8	KCNIP3 KCNIP2	7.39e-03	34	71	2	PF13833
Domain	Znf-RING_LisH	TRIM73 TRIM74	7.39e-03	34	71	2	IPR027370
Domain	zf-RING_UBOX	TRIM73 TRIM74	7.39e-03	34	71	2	PF13445
Pathway	KEGG_MEDICUS_REFERENCE_TYPE_II_INTERFERON_TO_JAK_STAT_SIGNALING_PATHWAY	JAK1 JAK2 IFNA7	9.23e-05	21	60	3	M47909
Pathway	BIOCARTA_IFNG_PATHWAY	JAK1 JAK2	2.64e-04	6	60	2	MM1590
Pathway	BIOCARTA_IFNG_PATHWAY	JAK1 JAK2	2.64e-04	6	60	2	M22085
Pathway	KEGG_MEDICUS_REFERENCE_IFN_RIPK1_3_SIGNALING_PATHWAY	JAK1 JAK2 IFNA7	3.03e-04	31	60	3	M47964
Pathway	REACTOME_NRCAM_INTERACTIONS	NRCAM DLG3	3.69e-04	7	60	2	M27378
Pathway	REACTOME_PHASE_1_INACTIVATION_OF_FAST_NA_CHANNELS	KCNIP3 KCNIP2	3.69e-04	7	60	2	M27457
Pathway	REACTOME_PHASE_1_INACTIVATION_OF_FAST_NA_CHANNELS	KCNIP3 KCNIP2	3.69e-04	7	60	2	MM15199
Pathway	BIOCARTA_STAT3_PATHWAY	JAK1 JAK2	4.91e-04	8	60	2	MM1576
Pathway	BIOCARTA_STAT3_PATHWAY	JAK1 JAK2	4.91e-04	8	60	2	M22063
Pathway	REACTOME_IFNG_SIGNALING_ACTIVATES_MAPKS	JAK1 JAK2	4.91e-04	8	60	2	M48010
Pathway	WP_INTERFERONMEDIATED_SIGNALING	JAK1 JAK2 IFNA7	5.14e-04	37	60	3	M39785
Pathway	REACTOME_MAPK1_ERK2_ACTIVATION	JAK1 JAK2	6.29e-04	9	60	2	M26918
Pathway	BIOCARTA_IL22BP_PATHWAY	JAK1 JAK2	6.29e-04	9	60	2	MM1419
Pathway	REACTOME_ROBO_RECEPTORS_BIND_AKAP5	PPP3CB ROBO2	6.29e-04	9	60	2	M27877
Pathway	BIOCARTA_IL22BP_PATHWAY	JAK1 JAK2	6.29e-04	9	60	2	M8066
Pathway	REACTOME_MAPK3_ERK1_ACTIVATION	JAK1 JAK2	7.84e-04	10	60	2	M26896
Pathway	REACTOME_INTERLEUKIN_6_SIGNALING	JAK1 JAK2	9.56e-04	11	60	2	M1014
Pathway	REACTOME_INTERLEUKIN_27_SIGNALING	JAK1 JAK2	9.56e-04	11	60	2	M27897
Pathway	PID_INTEGRIN4_PATHWAY	LAMA1 LAMA2	9.56e-04	11	60	2	M158
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	DOCK4 NRCAM SYNE1 RAB3GAP2 DZIP3 OTUD4 DLG3 SPEN	2.27e-06	407	73	8	12693553
Pubmed	Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.	DOCK4 SYNE1 SUPT7L PPP1R13B TMEM63A	2.40e-06	101	73	5	9872452
Pubmed	Transgenic overexpression of laminin alpha1 chain in laminin alpha2 chain-deficient mice rescues the disease throughout the lifespan.	LAMA1 LAMA2	4.35e-06	2	73	2	20544910
Pubmed	Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.	JAK2 PRKDC	4.35e-06	2	73	2	17764815
Pubmed	Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.	JAK1 JAK2	4.35e-06	2	73	2	28645562
Pubmed	Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2.	JAK1 JAK2	4.35e-06	2	73	2	35382859
Pubmed	Conserved neuron promoting activity in Drosophila and vertebrate laminin alpha1.	LAMA1 LAMA2	4.35e-06	2	73	2	8663504
Pubmed	Laminin α1 reduces muscular dystrophy in dy2J mice.	LAMA1 LAMA2	4.35e-06	2	73	2	29544677
Pubmed	Disruption of de novo fatty acid synthesis via acetyl-CoA carboxylase 1 inhibition prevents acute graft-versus-host disease.	ACACA TACC1	4.35e-06	2	73	2	27338930
Pubmed	Laminin 2 attachment selects myofibroblasts from fetal mouse lung.	LAMA1 LAMA2	4.35e-06	2	73	2	9728058
Pubmed	Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation.	JAK1 JAK2	4.35e-06	2	73	2	24169825
Pubmed	Lack of association of TNFAIP3 and JAK1 with Behçet's disease in the European population.	JAK1 TNFAIP3	4.35e-06	2	73	2	26005883
Pubmed	Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.	JAK1 JAK2	4.35e-06	2	73	2	21393331
Pubmed	Structure of human upstream binding factor HMG box 5 and site for binding of the cell-cycle regulatory factor TAF1.	UBTF TAF1	4.35e-06	2	73	2	17505112
Pubmed	Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.	JAK1 JAK2	4.35e-06	2	73	2	25977345
Pubmed	The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.	JAK1 JAK2	4.35e-06	2	73	2	24158701
Pubmed	Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.	JAK1 JAK2	4.35e-06	2	73	2	22684105
Pubmed	SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation.	JAK1 JAK2	4.35e-06	2	73	2	33827897
Pubmed	Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase.	JAK1 JAK2	4.35e-06	2	73	2	1848670
Pubmed	Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.	JAK1 JAK2	4.35e-06	2	73	2	29508247
Pubmed	Distinct roles for laminin globular domains in laminin alpha1 chain mediated rescue of murine laminin alpha2 chain deficiency.	LAMA1 LAMA2	4.35e-06	2	73	2	20657839
Pubmed	Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.	JAK1 JAK2	4.35e-06	2	73	2	33811972
Pubmed	Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.	JAK1 JAK2	4.35e-06	2	73	2	29263442
Pubmed	Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.	JAK1 JAK2	4.35e-06	2	73	2	27222478
Pubmed	Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.	JAK1 JAK2	4.35e-06	2	73	2	27903500
Pubmed	Two members of the JAK family of protein tyrosine kinases map to chromosomes 1p31.3 and 9p24.	JAK1 JAK2	4.35e-06	2	73	2	1581631
Pubmed	Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.	JAK1 JAK2	4.35e-06	2	73	2	19887489
Pubmed	Transcriptional repressor DREAM regulates T-lymphocyte proliferation and cytokine gene expression.	KCNIP3 KCNIP2	4.35e-06	2	73	2	16177826
Pubmed	Mapping the mammalian ribosome quality control complex interactome using proximity labeling approaches.	JAK1 DOCK4 ACACA OTUD4 CP ASPSCR1	4.39e-06	202	73	6	29540532
Pubmed	The E3-ubiquitin ligase TRIM50 interacts with HDAC6 and p62, and promotes the sequestration and clearance of ubiquitinated proteins into the aggresome.	TRIM73 SEC31B TRIM74	4.87e-06	16	73	3	22792322
Pubmed	TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B.	JAK1 JAK2 IFNA7	9.86e-06	20	73	3	11694501
Pubmed	CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.	JAK1 JAK2	1.30e-05	3	73	2	26175413
Pubmed	Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia.	JAK1 JAK2	1.30e-05	3	73	2	21537335
Pubmed	Janus kinases 1 and 2 regulate chemokine-mediated integrin activation and naïve T-cell homing.	JAK1 JAK2	1.30e-05	3	73	2	23526587
Pubmed	Progesterone activates Janus Kinase 1/2 and activators of transcription 1 (JAK1-2/STAT1) pathway in human spermatozoa.	JAK1 JAK2	1.30e-05	3	73	2	22748021
Pubmed	Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.	JAK1 JAK2	1.30e-05	3	73	2	17550976
Pubmed	Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.	JAK1 JAK2	1.30e-05	3	73	2	9548458
Pubmed	Multiple Kv channel-interacting proteins contain an N-terminal transmembrane domain that regulates Kv4 channel trafficking and gating.	KCNIP3 KCNIP2	1.30e-05	3	73	2	18957440
Pubmed	Jak3 maps to chromosome 8.	JAK1 JAK2	1.30e-05	3	73	2	8662243
Pubmed	Structural organization and chromosomal mapping of JAK3 locus.	JAK1 JAK2	1.30e-05	3	73	2	8934548
Pubmed	Foot-and-mouth disease virus structural protein VP3 degrades Janus kinase 1 to inhibit IFN-γ signal transduction pathways.	JAK1 JAK2	1.30e-05	3	73	2	26901336
Pubmed	Induction of Jak/STAT signaling by activation of the type 1 TNF receptor.	JAK1 JAK2	1.30e-05	3	73	2	9510175
Pubmed	Involvement of JAK1, JAK2, and JAK3 in Stimulation of Functional Activity of Mesenchymal Progenitor Cells by Fibroblast Growth Factor.	JAK1 JAK2	1.30e-05	3	73	2	27905037
Pubmed	Three lysine residues in the common β chain of the interleukin-5 receptor are required for Janus kinase (JAK)-dependent receptor ubiquitination, endocytosis, and signaling.	JAK1 JAK2	1.30e-05	3	73	2	21965659
Pubmed	Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function.	JAK1 JAK2	1.30e-05	3	73	2	20128689
Pubmed	A fundamental role for KChIPs in determining the molecular properties and trafficking of Kv4.2 potassium channels.	KCNIP3 KCNIP2	1.30e-05	3	73	2	12829703
Pubmed	Implication of JAK1, JAK2, and JAK3 in the Realization of Proliferation and Differentiation Potential of Mesenchymal Progenitor Cells In Vitro.	JAK1 JAK2	1.30e-05	3	73	2	27383175
Pubmed	Age-associated inflammation inhibits epidermal stem cell function.	JAK1 JAK2	1.30e-05	3	73	2	22972935
Pubmed	CHD1 acts via the Hmgpi pathway to regulate mouse early embryogenesis.	UBTFL6 UBTFL1	1.30e-05	3	73	2	26092847
Pubmed	Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.	JAK1 JAK2	1.30e-05	3	73	2	27554814
Pubmed	JAK mutations in high-risk childhood acute lymphoblastic leukemia.	JAK1 JAK2	1.30e-05	3	73	2	19470474
Pubmed	Gene structure variation in segmental duplication block C of human chromosome 7q 11.23 during primate evolution.	TRIM73 TRIM74	1.30e-05	3	73	2	26196062
Pubmed	Differential expression of laminin isoforms and alpha 6-beta 4 integrin subunits in the developing human and mouse intestine.	LAMA1 LAMA2	1.30e-05	3	73	2	7803849
Pubmed	LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease.	JAK1 JAK2	1.30e-05	3	73	2	21151131
Pubmed	A preliminary study of new single polymorphisms in the T helper type 17 pathway for psoriasis in the Korean population.	JAK1 JAK2	1.30e-05	3	73	2	27774581
Pubmed	Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components.	JAK1 JAK2	1.30e-05	3	73	2	8272873
Pubmed	The JAK1/2 Inhibitor Ruxolitinib Reverses Interleukin-6-Mediated Suppression of Drug-Detoxifying Proteins in Cultured Human Hepatocytes.	JAK1 JAK2	1.30e-05	3	73	2	29162613
Pubmed	Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction.	JAK1 JAK2	1.30e-05	3	73	2	8378315
Pubmed	Expression of laminin chains during myogenic differentiation.	LAMA1 LAMA2	1.30e-05	3	73	2	7510707
Pubmed	Jak2-mediated phosphorylation of Atoh1 is critical for medulloblastoma growth.	JAK2 PRKDC	1.30e-05	3	73	2	29168692
Pubmed	Dystroglycan is a binding protein of laminin and merosin in peripheral nerve.	LAMA1 LAMA2	1.30e-05	3	73	2	7925941
Pubmed	Laminin alpha1 chain mediated reduction of laminin alpha2 chain deficient muscular dystrophy involves integrin alpha7beta1 and dystroglycan.	LAMA1 LAMA2	1.30e-05	3	73	2	16504180
Pubmed	INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.	JAK1 JAK2	1.30e-05	3	73	2	20072651
Pubmed	Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130.	JAK1 JAK2	1.30e-05	3	73	2	10586060
Pubmed	YXXL motifs in SH2-Bbeta are phosphorylated by JAK2, JAK1, and platelet-derived growth factor receptor and are required for membrane ruffling.	JAK1 JAK2	1.30e-05	3	73	2	12551917
Pubmed	The Janus kinase family of protein tyrosine kinases and their role in signaling.	JAK1 JAK2	1.30e-05	3	73	2	10526570
Pubmed	Genome-wide identification of mouse congenital heart disease loci.	MKS1 DNAH11	1.30e-05	3	73	2	20511334
Pubmed	Amorfrutin A inhibits TNF-α induced JAK/STAT signaling, cell survival and proliferation of human cancer cells.	JAK1 JAK2	1.30e-05	3	73	2	28879797
Pubmed	Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.	JAK1 JAK2	1.30e-05	3	73	2	15923602
Pubmed	Protein tyrosine phosphorylation as a mechanism which regulates cytokine activation of early response genes.	JAK1 JAK2	1.30e-05	3	73	2	7539296
Pubmed	Piperlongumine inhibits gastric cancer cells via suppression of the JAK1,2/STAT3 signaling pathway.	JAK1 JAK2	1.30e-05	3	73	2	27053336
Pubmed	The transcription factor DREAM represses the deubiquitinase A20 and mediates inflammation.	TNFAIP3 KCNIP3	1.30e-05	3	73	2	24487321
Pubmed	Brain alpha-dystroglycan displays unique glycoepitopes and preferential binding to laminin-10/11.	LAMA1 LAMA2	1.30e-05	3	73	2	16709410
Pubmed	TRIM50 protein regulates vesicular trafficking for acid secretion in gastric parietal cells.	TRIM73 TRIM74	1.30e-05	3	73	2	22872646
Pubmed	Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs.	JAK1 JAK2	1.30e-05	3	73	2	32001089
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	JAK1 MAPK8IP1 PPP3CB NRCAM SYNE1 TLN2 DCLK2 PRKDC TAF1 CBFB SEC31B SLX4	1.41e-05	1285	73	12	35914814
Pubmed	Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method.	PPP3CB UBTF RASSF1 MYPN DZIP3 OTUD4 TNFAIP3 SLX4 SBNO2 CHST8 STK25	1.56e-05	1084	73	11	11544199
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	DOCK4 MAPK8IP1 FRMD4A ACACA NRCAM ACADL RAB3GAP2 DLG3 TLN2 TACC1 DCLK2	2.46e-05	1139	73	11	36417873
Pubmed	Differential distribution of KChIPs mRNAs in adult mouse brain.	KCNIP3 KCNIP2	2.60e-05	4	73	2	15363885
Pubmed	Dipyrithione inhibits IFN-gamma-induced JAK/STAT1 signaling pathway activation and IP-10/CXCL10 expression in RAW264.7 cells.	JAK1 JAK2	2.60e-05	4	73	2	20372968
Pubmed	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.	JAK1 JAK2	2.60e-05	4	73	2	20139093
Pubmed	Structure, alternative splicing, and expression of the human and mouse KCNIP gene family.	KCNIP3 KCNIP2	2.60e-05	4	73	2	16112838
Pubmed	Simultaneous activation of JAK1 and JAK2 confers IL-3 independent growth on Ba/F3 pro-B cells.	JAK1 JAK2	2.60e-05	4	73	2	15988755
Pubmed	CUZD1 is a critical mediator of the JAK/STAT5 signaling pathway that controls mammary gland development during pregnancy.	JAK1 JAK2	2.60e-05	4	73	2	28278176
Pubmed	Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases.	JAK1 JAK2	2.60e-05	4	73	2	8995399
Pubmed	Spermidine metabolism regulates leukemia stem and progenitor cell function through KAT7 expression in patient-derived mouse models.	PRKDC ABCD1	2.60e-05	4	73	2	39321266
Pubmed	The cell cycle regulatory factor TAF1 stimulates ribosomal DNA transcription by binding to the activator UBF.	UBTF TAF1	2.60e-05	4	73	2	12498690
Pubmed	Loss of JAK1 Drives Innate Immune Deficiency.	JAK1 JAK2	2.60e-05	4	73	2	30671064
Pubmed	Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases.	JAK1 JAK2	2.60e-05	4	73	2	9452495
Pubmed	Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.	JAK1 JAK2	2.60e-05	4	73	2	23406773
Pubmed	Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins.	JAK1 JAK2	2.60e-05	4	73	2	8657151
Pubmed	Modulation of A-type potassium channels by a family of calcium sensors.	KCNIP3 KCNIP2	2.60e-05	4	73	2	10676964
Pubmed	Specific effects of KChIP3/calsenilin/DREAM, but not KChIPs 1, 2 and 4, on calcium signalling and regulated secretion in PC12 cells.	KCNIP3 KCNIP2	2.60e-05	4	73	2	18393943
Pubmed	Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation.	JAK1 JAK2	2.60e-05	4	73	2	18430728
Pubmed	Laminin alpha 1, alpha 2, alpha 4 and beta 1 chain mRNA expression in mouse embryonic, neonatal, and adult hearts.	LAMA1 LAMA2	2.60e-05	4	73	2	9201115
Pubmed	Cytokine receptor-like factor 1 (CRLF1) protects against 6-hydroxydopamine toxicity independent of the gp130/JAK signaling pathway.	JAK1 JAK2	2.60e-05	4	73	2	23818941
Pubmed	JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor alpha and betac subunit, respectively, and are activated upon IL-5 stimulation.	JAK1 JAK2	2.60e-05	4	73	2	9516124
Pubmed	Delineation of the regions of interleukin-2 (IL-2) receptor beta chain important for association of Jak1 and Jak3. Jak1-independent functional recruitment of Jak3 to Il-2Rbeta.	JAK1 JAK2	2.60e-05	4	73	2	9553136
Pubmed	Involvement of Janus kinases in the insulin signaling pathway.	JAK1 JAK2	2.60e-05	4	73	2	8536716
Pubmed	IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis.	JAK1 JAK2	2.60e-05	4	73	2	22226123
GeneFamily	Ankyrin repeat domain containing\|FERM domain containing	JAK1 JAK2 FRMD4A TLN2	1.00e-05	50	49	4	1293
GeneFamily	Laminin subunits	LAMA1 LAMA2	4.67e-04	12	49	2	626
GeneFamily	Potassium voltage-gated channel regulatory subunits\|DASH family	KCNIP3 KCNIP2	7.39e-04	15	49	2	858
GeneFamily	Blood group antigens\|CD molecules\|I-set domain containing\|Immunoglobulin like domain containing	NRCAM MYPN ROBO2 ALPK2	9.40e-04	161	49	4	593
GeneFamily	OTU domain containing	OTUD4 TNFAIP3	9.53e-04	17	49	2	669
Coexpression	HALLMARK_COMPLEMENT	DOCK4 JAK2 CP TNFAIP3 KCNIP3 KCNIP2	1.74e-05	200	71	6	M5921
Coexpression	BONOME_OVARIAN_CANCER_SURVIVAL_SUBOPTIMAL_DEBULKING	SERPINB7 MAPK8IP1 FRMD4A PPP3CB SYNE1 DLG3 ASPSCR1 CHST8	6.69e-05	506	71	8	M253
Coexpression	LEE_AGING_NEOCORTEX_DN	CP PRKDC DBP IFNA7	6.69e-05	80	71	4	MM646
Coexpression	GSE40274_CTRL_VS_FOXP3_AND_EOS_TRANSDUCED_ACTIVATED_CD4_TCELL_UP	FRMD4A SNX20 DCLK2 ABCD1 TMEM63A	9.70e-05	169	71	5	M9102
Coexpression	LAKE_ADULT_KIDNEY_C26_MESANGIAL_CELLS	DOCK4 FRMD4A SYNE1 LAMA2 TACC1	1.20e-04	177	71	5	M39245
Coexpression	YAGI_AML_WITH_INV_16_TRANSLOCATION	DOCK4 TLN2 TACC1 TAF1 CBFB SPEN STK25	1.24e-04	411	71	7	M1047
Coexpression	PARENT_MTOR_SIGNALING_UP	JAK2 SYNE1 PAFAH2 LAMA2 CP DBP PAPSS1 MKS1	1.47e-04	567	71	8	M16909
Coexpression	ATF2_S_UP.V1_DN	SERPINB7 ACACA LAMA1 LAMA2 SBNO2	1.56e-04	187	71	5	M2681
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	JAK1 PPP3CB UBTF SYNE1 RAB3GAP2 DZIP3 OTUD4 TACC1 TNFAIP3 RFX7 CBFB SPEN SBNO2	1.65e-04	1492	71	13	M40023
Coexpression	PUJANA_BREAST_CANCER_LIT_INT_NETWORK	JAK1 JAK2 ACACA PRKDC	1.66e-04	101	71	4	M15356
Coexpression	GSE3982_DC_VS_NEUTROPHIL_DN	JAK1 ARAP3 DLG3 TNFAIP3 SPEN	1.99e-04	197	71	5	M5462
Coexpression	GSE29618_PRE_VS_DAY7_POST_LAIV_FLU_VACCINE_PDC_DN	JAK2 PPP3CB RAB3GAP2 PAFAH2 OTUD4	2.03e-04	198	71	5	M5001
Coexpression	GSE29618_LAIV_VS_TIV_FLU_VACCINE_DAY7_PDC_UP	JAK2 ACACA RAB3GAP2 OTUD4 TLN2	2.03e-04	198	71	5	M5018
Coexpression	GSE2585_CD80_HIGH_VS_LOW_AIRE_KO_MTEC_DN	SERPINB7 ARAP3 UBTFL1 AMDHD2 CP	2.08e-04	199	71	5	M6275
Coexpression	GSE37301_LYMPHOID_PRIMED_MPP_VS_GRAN_MONO_PROGENITOR_DN	ARAP3 RASSF1 AMDHD2 ASPSCR1 TACC1	2.08e-04	199	71	5	M8861
Coexpression	DOUGLAS_BMI1_TARGETS_DN	PAFAH2 AMDHD2 OTUD4 TACC1 TNFAIP3 TMEM63A	2.10e-04	314	71	6	M14279
Coexpression	GSE11961_FOLLICULAR_BCELL_VS_MEMORY_BCELL_DAY7_UP	JAK2 FRMD4A ACADL DZIP3 PPP1R13B	2.13e-04	200	71	5	M9338
Coexpression	GSE13306_TREG_VS_TCONV_LAMINA_PROPRIA_DN	SYNE1 PPP1R13B CP PAPSS1 ALPK2	2.13e-04	200	71	5	M3222
Coexpression	GSE41176_UNSTIM_VS_ANTI_IGM_STIM_BCELL_6H_DN	TCHH ACADL DBP SLC30A9 ALPK2	2.13e-04	200	71	5	M9923
Coexpression	GSE17721_0.5H_VS_8H_PAM3CSK4_BMDC_DN	JAK2 CP CBFB PAPSS1 TLR8	2.13e-04	200	71	5	M4111
Coexpression	GSE6259_FLT3L_INDUCED_33D1_POS_DC_VS_BCELL_DN	JAK1 PRKDC ABCD1 TAF1 TMEM63A	2.13e-04	200	71	5	M6745
ToppCell	Tracheal-NucSeq-Stromal-Myofibroblastic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	SEMA3D NRCAM SYNE1 PNCK TACC1 DCLK2 DNAH11	3.66e-08	198	73	7	c12e7511628db819a52959bb68580e27c00c2e41
ToppCell	Tracheal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	SEMA3D NRCAM SYNE1 PNCK DCLK2 DNAH11	8.97e-07	198	73	6	22e766df1276c5b14aa0d83f434f47140ebb98ea
ToppCell	LA-03._Atrial_Cardiomyocyte\|World / Chamber and Cluster_Paper	MYPN PPP1R13B ROBO2 TNNT1 ALPK2	1.44e-05	188	73	5	6d249fe92d51a19da19ec14bb2262d394255d577
ToppCell	facs-Lung-3m-Mesenchymal-fibroblast-alveolar_fibroblast\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DOCK4 NRCAM ROBO2 CP CHST8	1.56e-05	191	73	5	beb5bb42bd53bce01339da9110d374901548793c
ToppCell	facs-Lung-3m-Mesenchymal-fibroblast-alveolar_fibroblast-alveolar_fibroblast_l49\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DOCK4 NRCAM ROBO2 CP CHST8	1.56e-05	191	73	5	6609d85fd2577633dcc067507304a6f9e5865ca3
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Ascending_Vasa_Recta_Endothelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK4 SEMA3D ARAP3 TACC1 DCLK2	1.63e-05	193	73	5	1f978e102a029a6beb10913052cd0a20c7253e8e
ToppCell	droplet-Lung-21m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l49\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SEMA3D NRCAM LAMA2 CP PKDREJ	1.68e-05	194	73	5	7826fe5eb254ac032de0d978f39585a40e0b3ee4
ToppCell	E18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TCHH NRCAM ROBO2 CP TACC1	1.76e-05	196	73	5	617103f4a09e009fe96c28eb5e40505a4fd6dcf4
ToppCell	E18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TCHH NRCAM ROBO2 CP TACC1	1.76e-05	196	73	5	db64ab27374f82553ee577aec056141170f3656f
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK4 SEMA3D ARAP3 TACC1 DCLK2	1.76e-05	196	73	5	e224338490691d92c1f70b57112fabdcc92b06a9
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK4 SEMA3D ARAP3 TACC1 DCLK2	1.80e-05	197	73	5	c10dd1aaec01fb662eac83dfde90e3e426665d65
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAPK8IP1 SYNE1 SPATA18 DZIP3 DNAH11	1.80e-05	197	73	5	91637bdeab85024b5a02d1066f76cb803a2d6420
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAPK8IP1 SYNE1 SPATA18 DZIP3 DNAH11	1.80e-05	197	73	5	22c87dd15dc57bd0aa98a204c9fc9b3b9b573b45
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAPK8IP1 SYNE1 SPATA18 DZIP3 DNAH11	1.80e-05	197	73	5	3bbf068d2ad8196fbc85d3f311a7c54c9aece856
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAPK8IP1 SYNE1 SPATA18 DZIP3 DNAH11	1.80e-05	197	73	5	87db09f341e2b20eb6e1c3e917cb5c960387b3e9
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Endothelial\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK4 SEMA3D ARAP3 TACC1 DCLK2	1.80e-05	197	73	5	2844dbcd0a673ed81c99920aa45858651a00736d
ToppCell	Tracheal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_pulmonary\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	NRCAM SYNE1 TACC1 DCLK2 DNAH11	1.80e-05	197	73	5	ac4f53acb2f8a428b0f2fab3c30a34e095a1bed7
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	DOCK4 SEMA3D NRCAM SYNE1 LAMA1	1.94e-05	200	73	5	9b0916d8d07ac2bf1739f7be5296bf77ffee6094
ToppCell	PND07-Immune-Immune_Myeloid-DC-maDC\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	JAK2 SNX20 DCLK2 ALPK2	1.39e-04	160	73	4	7db30647b596f0c419087e6fabb9b99dcd5bddd4
ToppCell	PND07-Immune-Immune_Myeloid-DC-maDC-maDC_mature\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	JAK2 SNX20 DCLK2 ALPK2	1.39e-04	160	73	4	01f22cdb2a2f73776b7f91746e95c1850df94235
ToppCell	E16.5-samps-Mesenchymal-Matrix_fibroblast-_fetal-Mature_Fibroblast_1\|E16.5-samps / Age Group, Lineage, Cell class and subclass	DOCK4 TCHH CP TACC1	1.49e-04	163	73	4	f1ec2625b52664308968b01d8e0275e1e0751480
ToppCell	356C-Fibroblasts-Fibroblast-D\|356C / Donor, Lineage, Cell class and subclass (all cells)	LAMA1 LAMA2 DCLK2 KCNIP2	1.60e-04	166	73	4	7286a37b2827f3747469ffd0d76cbe81116db7ee
ToppCell	356C-Fibroblasts-Fibroblast-D-\|356C / Donor, Lineage, Cell class and subclass (all cells)	LAMA1 LAMA2 DCLK2 KCNIP2	1.60e-04	166	73	4	7c2eee0a4f45795a956acf936b85bdb35f1b1624
ToppCell	Children_(3_yrs)-Mesenchymal-myofibroblast_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NRCAM LAMA2 ROBO2 TLN2	1.60e-04	166	73	4	94636dbc039f794c735960c3425e00bdd5523602
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Stem_cells-neuroepithelial-like_cells\|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type.	ACACA PAFAH2 MKS1 PGBD3	1.63e-04	167	73	4	e488d9c7cf4355959e3833de3bd496c13fc11b1b
ToppCell	Control-Myeloid-MoAM1,_IL1R2\|Myeloid / Condition, Lineage and Cell class	DOCK4 ARAP3 SYNE1 LAMA2	1.63e-04	167	73	4	6e5140527437193f441ca96893b9a00d346614f3
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Glomerular_Capillary_Endothelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK4 ARAP3 SYNE1 TACC1	1.71e-04	169	73	4	987ff79ad563825dd9877ea8ccb536758f8c6700
ToppCell	droplet-Spleen-nan-3m-Myeloid-granulocyte\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TCHH ARAP3 SYNE1 TNNT1	1.75e-04	170	73	4	dbd6c9c7be824a1ff1b31af791064127cafbd194
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	FRMD4A SYNE1 LAMA2 ROBO2	1.83e-04	172	73	4	08a3fe536b1b064c5ee7779bc2b1115a5963a26b
ToppCell	COVID-19-kidney-PEC\|kidney / Disease (COVID-19 only), tissue and cell type	FRMD4A SYNE1 ROBO2 ALPK2	1.83e-04	172	73	4	36a96714a0eb6ac438648135336c9791881ddadb
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	FRMD4A SYNE1 LAMA2 ROBO2	1.83e-04	172	73	4	553701349444eb366df3c11f54bb093434f153c6
ToppCell	droplet-Lung-3m-Hematologic-myeloid-Basophil/Mast_cell-basophil_l26\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	JAK2 PAFAH2 TNFAIP3 SEC31B	1.87e-04	173	73	4	120dd20e8a71f9169a1596b6171df7aa0b96dd15
ToppCell	droplet-Lung-3m-Hematologic-myeloid-Basophil/Mast_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	JAK2 PAFAH2 TNFAIP3 SEC31B	1.87e-04	173	73	4	b2c55084ef6dac0e329c2e65c24cfe0045859c30
ToppCell	facs-Diaphragm-Limb_Muscle-24m-Mesenchymal-skeletal_muscle_satellite_cell\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NRBP2 MYPN TLN2 SBNO2	1.91e-04	174	73	4	f230d23618a6487f2664efb2c677e0a4559e2bf4
ToppCell	3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-myocytic_fibroblast-Myofibroblasts-Myofibroblasts_L.2.3.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NRCAM LAMA2 ROBO2 TLN2	1.95e-04	175	73	4	1799a7be623dc3bf53ba580a7c47d2619969d708
ToppCell	droplet-Kidney-KIDNEY-30m-Mesenchymal-podocyte\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SUPT7L CP PRKDC CHST8	1.95e-04	175	73	4	31f0fb2e47e357dbf9c15436b7df85b3c370ded7
ToppCell	COVID-19-kidney-Epi_(Mes)\|kidney / Disease (COVID-19 only), tissue and cell type	FRMD4A SYNE1 CP ALPK2	2.13e-04	179	73	4	e7c9dc63f03d3f3746b51a7e3c8393089e2ceb7d
ToppCell	Children_(3_yrs)-Mesenchymal-myofibroblast_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NRCAM LAMA2 ROBO2 TLN2	2.17e-04	180	73	4	01f2e5d96016823482f89ba503d007d4bd88eeac
ToppCell	E18.5-samps-Mesenchymal-Matrix_fibroblast\|E18.5-samps / Age Group, Lineage, Cell class and subclass	DOCK4 ROBO2 CP TACC1	2.27e-04	182	73	4	ceb37c214662a48efb56ab0d015977c6fab478b0
ToppCell	facs-Skin-Anagen-3m-Epithelial-Basal_IFE\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SERPINB7 SEMA3D TNFAIP3 SBNO2	2.27e-04	182	73	4	22d6f4790950508e8aa27e02a8133af5f53f13c8
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NRCAM LAMA1 TLN2 DNAH11	2.36e-04	184	73	4	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	P28-Mesenchymal-mesenchymal_fibroblast-alveolar_fibroblast_Wnt2-pa\|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	NRCAM ROBO2 CP TACC1	2.36e-04	184	73	4	924400f47e6b2cdf7b0d538df75857935cf0209b
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NRCAM LAMA1 TLN2 DNAH11	2.36e-04	184	73	4	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NRCAM LAMA1 TLN2 DNAH11	2.36e-04	184	73	4	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	COVID-19-Heart-CM_2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	MYPN LAMA2 TNNT1 ALPK2	2.41e-04	185	73	4	549eeb521c3985bff396ea0f202db21822efa51f
ToppCell	mild_COVID-19_(asymptomatic)-gd_T\|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2)	SYNE1 RASSF1 TNFAIP3 TRIM74	2.46e-04	186	73	4	5fa3ed834898aa06aae15a8ade7ab93a6e4744f8
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 LAMA1 PPP1R13B DNAH11	2.46e-04	186	73	4	f0c8de4f6ae9047b9108a47a2af8c5f42bc103b0
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_II-F\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	DOCK4 FRMD4A TCHH TNFAIP3	2.51e-04	187	73	4	98026c1aaf8de280470ad75536121357934fc78d
ToppCell	facs-Skin-Telogen-3m-Epithelial-basal_cell_of_epidermis\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SERPINB7 SEMA3D RASSF1 TNFAIP3	2.51e-04	187	73	4	9c1013720c248ef201d010806b6e7ad24205e8ee
ToppCell	Control-Fibroblasts-Other_FB\|Control / group, cell type (main and fine annotations)	NRCAM LAMA2 ROBO2 TLN2	2.51e-04	187	73	4	bd3739c4a52aa1ba5deffd778e113a9800f7e158
ToppCell	wk_08-11-Mesenchymal-Mesothelial-Early_mesothelial\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	SEMA3D SLC5A12 DBP TNNT1	2.57e-04	188	73	4	6151051c027c7ff7d5d4bf5f1e11d7fe58eb22ed
ToppCell	Control-Fibroblasts-Adventitial_FB\|Control / group, cell type (main and fine annotations)	SEMA3D LAMA2 ROBO2 TLN2	2.57e-04	188	73	4	706a26c372add839d947749f0521a0e1f5c9b0ec
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-3m-Macroglial-oligodendrocyte_precursor_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SEMA3D TCHH NRCAM KCNIP3	2.57e-04	188	73	4	a244fcd092d5bd544e503366b1439b0fbc1ee00e
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-3m-Macroglial-Oligodendrocyte_progenitor_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SEMA3D TCHH NRCAM KCNIP3	2.57e-04	188	73	4	c8530c9ff98666c64a94683261af4288cb790a7e
ToppCell	facs-Skin-Telogen-3m-Epithelial-Basal_IFE\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SERPINB7 SEMA3D RASSF1 TNFAIP3	2.57e-04	188	73	4	8cc927b4c51d982fdafa04dc7393617ad9bb220e
ToppCell	renal_medulla_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	NRCAM SYNE1 LAMA1 TACC1	2.62e-04	189	73	4	830d9cd0dd706bce22eb2416f07b2c31c870a05a
ToppCell	Mesenchymal-pericyte_cell\|World / Lineage, Cell type, age group and donor	NRCAM LAMA2 TACC1 DCLK2	2.62e-04	189	73	4	d7ed96add29f219183c802895fbff519b627f635
ToppCell	droplet-Heart-nan-18m-Neuronal-cardiac_neuron\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAPK8IP1 NRBP2 NRCAM MKS1	2.62e-04	189	73	4	0493f7b79127c207fd7ade778ef4810500495d7e
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Ascending_Vasa_Recta_Endothelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK4 SEMA3D ARAP3 TACC1	2.67e-04	190	73	4	656483751e4bf137e4e4bfb2a03a478a8f7fcb63
ToppCell	RV-15._Ventricular_Cardiomyocyte_III\|RV / Chamber and Cluster_Paper	JAK2 MYPN LAMA2 ALPK2	2.67e-04	190	73	4	93c3188dfeb0b2f9889f8ae9b9c1f2f34129c99b
ToppCell	COVID-19-kidney-AQP1+SLC14A1+EC\|kidney / Disease (COVID-19 only), tissue and cell type	DOCK4 ARAP3 CP TACC1	2.67e-04	190	73	4	1519f34d31fe0817184c5865a0bc9f0cb479b1a4
ToppCell	356C-Epithelial_cells-Epithelial-F_(Ciliated)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	SPATA18 DZIP3 CP DNAH11	2.72e-04	191	73	4	dad675251e129254955eac179c84a641a4864586
ToppCell	E16.5-samps-Mesenchymal-Matrix_fibroblast-_fetal\|E16.5-samps / Age Group, Lineage, Cell class and subclass	DOCK4 TCHH NRCAM CP	2.72e-04	191	73	4	3379d145d34f89150f7b06d1340022cfc6b4a6ce
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	FRMD4A NRCAM ROBO2 SBNO2	2.72e-04	191	73	4	08720998aa55131d7377c4c67c4c935865bd7d79
ToppCell	356C-Epithelial_cells-Epithelial-F_(Ciliated)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	SPATA18 DZIP3 CP DNAH11	2.72e-04	191	73	4	6d2cf41ee946137c039ddcc13593fc3f670afbba
ToppCell	PND01-03-samps-Mesenchymal-Matrix_fibroblast-MatrixFB-A\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	DOCK4 ROBO2 CP TACC1	2.72e-04	191	73	4	e7c605b56934d1383237c1f946dbccef25d91368
ToppCell	RA-09._Endothelium_I\|World / Chamber and Cluster_Paper	DOCK4 ARAP3 SYNE1 TACC1	2.72e-04	191	73	4	c8a0c2af119bc34a8f694a7d30642f28002c84b9
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Ascending_Vasa_Recta_Endothelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK4 SEMA3D ARAP3 TACC1	2.78e-04	192	73	4	1ee4783051ec94ea94600f040edcb385fc4289f1
ToppCell	Bronchial_Biopsy-Epithelial-Ciliated_1\|Bronchial_Biopsy / Tissue, Lineage and Cell class of Lung Cells from 10X	SYNE1 SPATA18 DZIP3 DNAH11	2.78e-04	192	73	4	be592e661367affced9ebe80849b466e6adb3a34
ToppCell	RA-09._Endothelium_I\|RA / Chamber and Cluster_Paper	DOCK4 ARAP3 SYNE1 TACC1	2.78e-04	192	73	4	8a1b1c3e83a68ad74f8f4eb00455c9e41aa57cfc
ToppCell	ASK452-Epithelial-Ciliated\|Epithelial / Donor, Lineage and Cell class of Lung cells from Dropseq	SPATA18 DZIP3 CP DNAH11	2.83e-04	193	73	4	c0d10075862ac878aa05fc49c8b73e470783bf16
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	DOCK4 SEMA3D LAMA2 ROBO2	2.83e-04	193	73	4	9f69edc97b868d23998abc98928a2e89a885ef8a
ToppCell	PND28-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_mature\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	NRCAM LAMA2 ROBO2 CP	2.83e-04	193	73	4	4c74a3f69b2cbdf139e7e66b44bd86869ac34dc0
ToppCell	PND28-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	NRCAM LAMA2 ROBO2 CP	2.83e-04	193	73	4	ff8ceeb3cfd1bef7239df490c19d181091750833
ToppCell	IPF-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	SYNE1 SPATA18 DZIP3 DNAH11	2.83e-04	193	73	4	ad58f5080e0ba65c845056ea6b79037b636e9c64
ToppCell	facs-Liver-Liver_non-hepato/SCs-18m-Endothelial-nan\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARAP3 ROBO2 TLN2 TACC1	2.83e-04	193	73	4	2483bb7f398e4fa0ef09c8bd584ed25703853f03
ToppCell	Bronchial_Biopsy-Epithelial-Ciliated_1\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	SYNE1 SPATA18 DZIP3 DNAH11	2.83e-04	193	73	4	0b62a6ddd7c42efd9f39781971d1438501e1fa8d
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK4 SEMA3D ARAP3 TACC1	2.83e-04	193	73	4	287e756d5fd3bd2931c168da24beaa0d02a350ae
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAPK8IP1 SPATA18 DZIP3 DNAH11	2.89e-04	194	73	4	3cd90d01ed5a5ce65aad8284dab2537ec16e3d7c
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DOCK4 LAMA2 ROBO2 TLN2	2.89e-04	194	73	4	e93de9428c986b8943fc169258847c650cfab0e5
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	DOCK4 FRMD4A LAMA2 ROBO2	2.89e-04	194	73	4	011e14d9ed1393275f892060e7708ffadcd0767f
ToppCell	PND01-03-samps-Mesenchymal\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	DOCK4 ROBO2 CP TACC1	2.89e-04	194	73	4	4f9bd0ded0dde1df885850714f29e73e992539a5
ToppCell	Bronchial_Brush-Epithelial-Ciliated_1\|Bronchial_Brush / Tissue, Lineage and Cell class of Lung Cells from 10X	SYNE1 SPATA18 DZIP3 DNAH11	2.89e-04	194	73	4	b4ce60c06568123008b1081d644733cb91c28f51
ToppCell	Bronchial_Brush-Epithelial-Ciliated_1\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	SYNE1 SPATA18 DZIP3 DNAH11	2.89e-04	194	73	4	7a7ddccfe72a4a0dc4d1a5c809988f0069f9f1a3
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ACACA ACADL SYNE1 PPP1R13B	2.89e-04	194	73	4	97534c8bba895a7913665e03ae4e5c4a6ad71daf
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Ascending_Vasa_Recta_Endothelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK4 SEMA3D ARAP3 SYNE1	2.89e-04	194	73	4	ad6c04ad0621689e3bf4c94ccd6e60653bbd02c7
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Mesenchymal-Pericytes-Immature_pericyte\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TLN2 TACC1 DCLK2 DNAH11	2.89e-04	194	73	4	3b9ada901dfe7a5cc4861a883d3268c53b11e5b6
ToppCell	PND10-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_mature\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	NRCAM ROBO2 CP TACC1	2.95e-04	195	73	4	1c1135be421af98cd0077bec1ff2c4158d42aa21
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)-Multiciliated_(nasal)_L.0.3.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAPK8IP1 SPATA18 DZIP3 DNAH11	2.95e-04	195	73	4	79dc031258579ea328181dda33710dd897f1064a
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAPK8IP1 SPATA18 DZIP3 DNAH11	2.95e-04	195	73	4	db4270c135c392ed443670981656e3cd5b95939d
ToppCell	moderate-Epithelial-Ciliated\|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	SYNE1 SPATA18 DZIP3 DNAH11	2.95e-04	195	73	4	3486eae5fdb062a75a907b896c9d7b396d2aa195
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAPK8IP1 SPATA18 DZIP3 DNAH11	2.95e-04	195	73	4	6365e3893e38231090ec2dbef010dec71dea3d07
ToppCell	PND10-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	NRCAM ROBO2 CP TACC1	2.95e-04	195	73	4	1f005ee1da66b539bd200aaa98f46edbbc7f12e4
ToppCell	E17.5-Mesenchymal-mesenchymal_fibroblast-alveolar_fibroblast_Wnt2-pa\|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TCHH NRCAM CP TACC1	2.95e-04	195	73	4	b072fdc2131173f562e55dd78226eaf2c57d3690
ToppCell	COVID-19_Severe-Lymphoid_T/NK-gd_T\|COVID-19_Severe / Disease group, lineage and cell class	SYNE1 RASSF1 PAFAH2 LAMA2	2.95e-04	195	73	4	9990440bda7fac5d00ef80444fab07459be625e1
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	DOCK4 ACACA ZCCHC7 RFX7	3.01e-04	196	73	4	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	COVID-19-kidney-VWF+PLVAP+VCAM1+EC\|kidney / Disease (COVID-19 only), tissue and cell type	DOCK4 SEMA3D ARAP3 TACC1	3.01e-04	196	73	4	ac2c4a325efa8497a755cd31fb6a9d94d8e3bf42
ToppCell	PND01-03-samps-Mesenchymal-Matrix_fibroblast\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	DOCK4 ROBO2 CP TACC1	3.01e-04	196	73	4	54f4cf778f95a9ff662e5c7520916a25e605bf95
ToppCell	E18.5-Mesenchymal-Mesenchymal_structural\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TCHH ROBO2 CP TACC1	3.01e-04	196	73	4	97e26622d9582b092c18ff5b7e957818f99d9631
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	SYNE1 RASSF1 PAFAH2 LAMA2	3.01e-04	196	73	4	418e8e0a51c5cb60e3b903e7d2d800dc8b9f3d5c
Drug	Flufenamic acid [530-78-9]; Up 200; 14.2uM; PC3; HT_HG-U133A	JAK2 UBTF SYNE1 PAFAH2 TAF1 CHST8 TMEM63A	2.31e-06	195	70	7	2104_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	FRMD4A UBTF RASSF1 DLG3 ASPSCR1 SBNO2	1.40e-05	170	70	6	5417_DN
Drug	Cyclobenzaprine hydrochloride [6202-23-9]; Up 200; 12.8uM; HL60; HT_HG-U133A	ARAP3 PAFAH2 ASPSCR1 ABCD1 TNFAIP3 TLR8	2.79e-05	192	70	6	1332_UP
Drug	Tiletamine hydrochloride; Down 200; 15.4uM; MCF7; HT_HG-U133A	UBTF RASSF1 SUPT7L LSS SBNO2 TMEM63A	2.79e-05	192	70	6	6013_DN
Drug	Carcinine [56897-53-1]; Down 200; 22uM; PC3; HT_HG-U133A	PAFAH2 ASPSCR1 DBP SBNO2 TMEM63A STK25	2.87e-05	193	70	6	4225_DN
Drug	carbamazepine; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA	JAK2 RASSF1 SUPT7L SPEN SBNO2 STK25	2.87e-05	193	70	6	835_DN
Drug	Tropicamide [1508-75-4]; Down 200; 14uM; MCF7; HT_HG-U133A	FRMD4A PAFAH2 LSS TNFAIP3 SBNO2 TMEM63A	2.95e-05	194	70	6	3619_DN
Drug	Methacycline hydrochloride [3963-95-9]; Down 200; 8.4uM; HL60; HT_HG-U133A	SYNE1 RAB3GAP2 PAFAH2 LSS ABCD1 SEC31B	3.04e-05	195	70	6	2901_DN
Drug	Harpagoside [19210-12-9]; Down 200; 8uM; HL60; HT_HG-U133A	ARAP3 NRCAM PAFAH2 TNNT1 SBNO2 TMEM63A	3.13e-05	196	70	6	2935_DN
Drug	Midecamycin [35457-80-8]; Down 200; 5uM; MCF7; HT_HG-U133A	UBTF SUPT7L DZIP3 ASPSCR1 TNFAIP3 STK25	3.22e-05	197	70	6	1526_DN
Drug	dexamethasone; Up 200; 1uM; MCF7; HG-U133A	TCHH RASSF1 RAB3GAP2 TLN2 DBP SBNO2	3.22e-05	197	70	6	255_UP
Drug	Spiramycin [8025-81-8]; Down 200; 4.8uM; HL60; HT_HG-U133A	RAB3GAP2 LSS TNNT1 SBNO2 CHST8 TMEM63A	3.22e-05	197	70	6	2558_DN
Drug	Epitiostanol [2363-58-8]; Down 200; 13uM; MCF7; HT_HG-U133A	FRMD4A RAB3GAP2 TACC1 ABCD1 TNFAIP3 TMEM63A	3.22e-05	197	70	6	7342_DN
Drug	sulfate	JAK2 MAPK8IP1 LAMA1 AMDHD2 LAMA2 ROBO2 CP DLG3 TAF1 TNFAIP3 PAPSS1 IFNA7 PGBD3 CHST8	3.25e-05	1292	70	14	CID000001117
Drug	Flucytosine [2022-85-7]; Up 200; 31uM; MCF7; HT_HG-U133A	SUPT7L PAFAH2 LSS TAF1 TNFAIP3 TMEM63A	3.31e-05	198	70	6	5289_UP
Drug	Levopropoxyphene napsylate [5714-90-9]; Down 200; 7.4uM; PC3; HT_HG-U133A	UBTF PAFAH2 DZIP3 ASPSCR1 TNFAIP3 TMEM63A	3.31e-05	198	70	6	5083_DN
Drug	Fenofibrate [49562-28-9]; Down 200; 11uM; MCF7; HT_HG-U133A	RASSF1 PAFAH2 DZIP3 TNFAIP3 RFX7 TMEM63A	3.31e-05	198	70	6	7474_DN
Drug	Prazosin hydrochloride [19237-84-4]; Up 200; 9.6uM; PC3; HT_HG-U133A	JAK2 FRMD4A TAF1 TNFAIP3 DBP SBNO2	3.31e-05	198	70	6	6315_UP
Drug	clozapine; Down 200; 10uM; MCF7; HT_HG-U133A_EA	SUPT7L PAFAH2 TACC1 ABCD1 TMEM63A STK25	3.31e-05	198	70	6	1009_DN
Drug	Methacycline hydrochloride [3963-95-9]; Down 200; 8.4uM; PC3; HT_HG-U133A	JAK2 PAFAH2 TLN2 TNFAIP3 SBNO2 TMEM63A	3.31e-05	198	70	6	4062_DN
Drug	(+,-)-Octopamine hydrochloride [770-05-8]; Down 200; 21uM; MCF7; HT_HG-U133A	DOCK4 JAK2 DZIP3 ASPSCR1 SBNO2 TMEM63A	3.40e-05	199	70	6	6491_DN
Drug	Pizotifen malate [5189-11-7]; Down 200; 9.4uM; MCF7; HT_HG-U133A	DOCK4 JAK2 TCHH NRCAM UBTF DZIP3	3.40e-05	199	70	6	6513_DN
Drug	magnolol	JAK1 JAK2 SYNE1 TNFAIP3	3.51e-05	60	70	4	CID000072300
Drug	4-octyne	SYNE1 CP	5.57e-05	4	70	2	CID000016029
Drug	quinazoline	JAK1 SYNE1 SUPT7L PRKDC	6.81e-05	71	70	4	CID000009210
Drug	dimethoxyphenol	SYNE1 CP	1.39e-04	6	70	2	CID000078828
Drug	2,6-di-tert-butylpyridine	SYNE1 CP	1.39e-04	6	70	2	CID000068510
Drug	sodium acetylacetonate	ACACA SYNE1 CP	1.42e-04	33	70	3	CID000018630
Drug	propacetamol	ABCD1 DBP	1.94e-04	7	70	2	CID000068865
Drug	AC1MNCFH	SYNE1 CP	1.94e-04	7	70	2	CID003301780
Drug	CpCp	ACACA CP	1.94e-04	7	70	2	CID000193370
Drug	baricitinib	JAK1 JAK2	1.94e-04	7	70	2	ctd:C000596027
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A	JAK2 NRCAM UBTF DLG3 SBNO2	2.05e-04	175	70	5	6891_DN
Drug	ferrocene	ACADL SYNE1 CP	2.17e-04	38	70	3	CID000007611
Drug	Mefloquine hydrochloride [51773-92-3]; Up 200; 9.6uM; MCF7; HT_HG-U133A	DOCK4 LSS TNFAIP3 SBNO2 TMEM63A	2.46e-04	182	70	5	6205_UP
Drug	PhLi	ACACA SYNE1	2.58e-04	8	70	2	CID000637932
Drug	Withaferin A [5119-48-2]; Down 200; 1uM; MCF7; HT_HG-U133A	JAK2 DZIP3 TACC1 TNFAIP3 MKS1	2.71e-04	186	70	5	3902_DN
Drug	Cantharidin [56-25-7]; Down 200; 20.4uM; HL60; HT_HG-U133A	JAK2 UBTF RAB3GAP2 OTUD4 TMEM63A	2.78e-04	187	70	5	3075_DN
Drug	ICI182,780; Down 200; 1uM; MCF7; HT_HG-U133A	JAK2 SUPT7L TLN2 SBNO2 STK25	2.85e-04	188	70	5	7091_DN
Drug	Phenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A	DOCK4 JAK2 FRMD4A OTUD4 ABCD1	2.92e-04	189	70	5	5248_DN
Drug	Securinine [5610-40-2]; Down 200; 18.4uM; MCF7; HT_HG-U133A	FRMD4A PAFAH2 TLN2 TACC1 DBP	2.92e-04	189	70	5	6831_DN
Drug	Eburnamonine (-) [4880-88-0]; Down 200; 13.6uM; PC3; HT_HG-U133A	ARAP3 DZIP3 DLG3 TAF1 TMEM63A	2.99e-04	190	70	5	7154_DN
Drug	Antimycin A [1397-94-0]; Down 200; 7.2uM; MCF7; HT_HG-U133A	DOCK4 TCHH UBTF ASPSCR1 SBNO2	3.07e-04	191	70	5	2261_DN
Drug	Dienestrol [84-17-3]; Up 200; 15uM; MCF7; HT_HG-U133A	TCHH RASSF1 TNFAIP3 SBNO2 TMEM63A	3.07e-04	191	70	5	3448_UP
Drug	Famprofazone [22881-35-2]; Down 200; 10.6uM; PC3; HT_HG-U133A	JAK2 SYNE1 PAFAH2 CHST8 TMEM63A	3.14e-04	192	70	5	3753_DN
Drug	PHA-00851261E [724719-49-7]; Down 200; 10uM; PC3; HT_HG-U133A	PAFAH2 DLG3 ASPSCR1 SBNO2 TMEM63A	3.14e-04	192	70	5	4330_DN
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A	TCHH NRCAM AMDHD2 TNNT1 TMEM63A	3.14e-04	192	70	5	3114_UP
Drug	TMEDA	ACACA SYNE1 TNNT1	3.14e-04	43	70	3	CID000008037
Drug	C768-0445; Down 200; 10uM; MCF7; HT_HG-U133A_EA	RASSF1 SUPT7L LSS CBFB TMEM63A	3.22e-04	193	70	5	865_DN
Drug	Ceforanide [60925-61-3]; Down 200; 7.6uM; PC3; HT_HG-U133A	JAK2 UBTF DZIP3 LSS PRKDC	3.22e-04	193	70	5	6751_DN
Drug	trichostatin A; Down 200; 0.1uM; ssMCF7; HG-U133A	JAK2 ACACA UBTF ASPSCR1 SBNO2	3.22e-04	193	70	5	413_DN
Drug	Tocainide hydrochloride; Up 200; 17.4uM; MCF7; HT_HG-U133A	UBTF PAFAH2 LSS ASPSCR1 PRKDC	3.30e-04	194	70	5	4838_UP
Drug	Nafronyl oxalate [3200-06-4]; Up 200; 8.4uM; HL60; HT_HG-U133A	OTUD4 LSS ASPSCR1 SBNO2 CHST8	3.30e-04	194	70	5	1267_UP
Drug	Primaquine diphosphate [63-45-6]; Down 200; 8.8uM; PC3; HT_HG-U133A	JAK2 RAB3GAP2 SUPT7L DLG3 ASPSCR1	3.30e-04	194	70	5	4263_DN
Drug	Morantel tartrate [26155-31-7]; Down 200; 10.8uM; MCF7; HT_HG-U133A	RASSF1 SUPT7L TACC1 SPEN TMEM63A	3.30e-04	194	70	5	1676_DN
Drug	Lynestrenol [52-76-6]; Up 200; 14uM; MCF7; HT_HG-U133A	JAK2 OTUD4 TAF1 TNFAIP3 TMEM63A	3.30e-04	194	70	5	5355_UP
Drug	Tiletamine hydrochloride; Down 200; 15.4uM; MCF7; HT_HG-U133A	AMDHD2 DZIP3 OTUD4 CHST8 TMEM63A	3.30e-04	194	70	5	6516_DN
Drug	U794	SYNE1 CP	3.31e-04	9	70	2	CID000017548
Drug	SDMP	ACACA SYNE1	3.31e-04	9	70	2	CID000094924
Drug	dodecanal	ABCD1 SPEN	3.31e-04	9	70	2	CID000008194
Drug	pyranone	SYNE1 ASPSCR1	3.31e-04	9	70	2	CID000119838
Drug	thietane	SYNE1 CP	3.31e-04	9	70	2	CID000009251
Drug	Medrysone [2668-66-8]; Down 200; 11.6uM; PC3; HT_HG-U133A	JAK2 SUPT7L PAFAH2 TLN2 SBNO2	3.37e-04	195	70	5	3705_DN
Drug	Androsterone [53-41-8]; Down 200; 13.8uM; HL60; HT_HG-U133A	JAK2 UBTF RASSF1 ABCD1 SPEN	3.37e-04	195	70	5	1296_DN
Drug	PF-00875133-00 [351322-64-0]; Down 200; 10uM; MCF7; HT_HG-U133A	FRMD4A TCHH ASPSCR1 TACC1 CHST8	3.37e-04	195	70	5	5967_DN
Drug	Metolazone [17560-51-9]; Down 200; 11uM; MCF7; HT_HG-U133A	PAFAH2 TLN2 LSS MKS1 SBNO2	3.37e-04	195	70	5	1514_DN
Drug	Rapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A	UBTF RAB3GAP2 SUPT7L LSS TACC1	3.37e-04	195	70	5	1162_DN
Drug	Ozagrel hydrochloride [78712-43-3]; Up 200; 15.2uM; HL60; HT_HG-U133A	JAK2 LSS SBNO2 TMEM63A STK25	3.37e-04	195	70	5	2942_UP
Drug	Mycophenolic acid [24280-93-1]; Down 200; 12.4uM; PC3; HT_HG-U133A	RASSF1 OTUD4 TLN2 TAF1 TMEM63A	3.37e-04	195	70	5	4019_DN
Drug	Gemfibrozil [25812-30-0]; Up 200; 16uM; PC3; HT_HG-U133A	UBTF SYNE1 PAFAH2 DLG3 TMEM63A	3.37e-04	195	70	5	2113_UP
Drug	Beta-sistosterol [83-46-5]; Down 200; 9.6uM; PC3; HT_HG-U133A	SYNE1 RAB3GAP2 PAFAH2 SBNO2 TMEM63A	3.37e-04	195	70	5	4073_DN
Drug	Cyclopenthiazide [742-20-1]; Down 200; 10.6uM; PC3; HT_HG-U133A	JAK2 SUPT7L PAFAH2 TAF1 TMEM63A	3.37e-04	195	70	5	4229_DN
Drug	Ranitidine hydrochloride [66357-59-3]; Down 200; 11.4uM; MCF7; HT_HG-U133A	JAK2 TLN2 LSS TNFAIP3 SBNO2	3.45e-04	196	70	5	5425_DN
Drug	Debrisoquin sulfate [581-88-4]; Up 200; 9uM; MCF7; HT_HG-U133A	FRMD4A LSS TAF1 SPEN STK25	3.45e-04	196	70	5	5288_UP
Drug	Diprophylline [479-18-5]; Down 200; 15.8uM; PC3; HT_HG-U133A	SYNE1 TLN2 ASPSCR1 SBNO2 TMEM63A	3.45e-04	196	70	5	5063_DN
Drug	Estrone [53-16-7]; Up 200; 14.8uM; PC3; HT_HG-U133A	NRCAM RAB3GAP2 LSS TNFAIP3 TMEM63A	3.45e-04	196	70	5	6647_UP
Drug	Spiramycin [8025-81-8]; Down 200; 4.8uM; PC3; HT_HG-U133A	FRMD4A SUPT7L ASPSCR1 DBP TMEM63A	3.45e-04	196	70	5	3762_DN
Drug	Epivincamine [6835-99-0]; Down 200; 11.2uM; PC3; HT_HG-U133A	SYNE1 PAFAH2 LSS ASPSCR1 TMEM63A	3.45e-04	196	70	5	4500_DN
Drug	Flupentixol dihydrochloride cis-(Z) [2413-38-9]; Up 200; 7.8uM; MCF7; HT_HG-U133A	RASSF1 SUPT7L TLN2 LSS STK25	3.45e-04	196	70	5	5307_UP
Drug	Delcorine; Down 200; 8.4uM; MCF7; HT_HG-U133A	JAK2 PAFAH2 OTUD4 TLN2 TMEM63A	3.45e-04	196	70	5	3613_DN
Drug	fluphenazine dihydrochloride; Down 200; 10uM; MCF7; HG-U133A	ACACA AMDHD2 TLN2 SBNO2 TMEM63A	3.54e-04	197	70	5	490_DN
Drug	Carbimazole [22232-54-8]; Up 200; 21.4uM; MCF7; HT_HG-U133A	DOCK4 SYNE1 DZIP3 TNFAIP3 CHST8	3.54e-04	197	70	5	3299_UP
Drug	Trolox [53188-07-1]; Up 200; 16uM; PC3; HT_HG-U133A	RASSF1 PAFAH2 TLN2 TNFAIP3 TMEM63A	3.54e-04	197	70	5	7304_UP
Drug	Nitrofural [59-87-0]; Up 200; 20.2uM; MCF7; HT_HG-U133A	PAFAH2 DLG3 TLN2 ABCD1 STK25	3.54e-04	197	70	5	5321_UP
Drug	Piperine [94-62-2]; Up 200; 14uM; HL60; HT_HG-U133A	DOCK4 PAFAH2 ASPSCR1 TLR8 TMEM63A	3.54e-04	197	70	5	1327_UP
Drug	Furaltadone hydrochloride [3759-92-0]; Down 200; 11uM; HL60; HT_HG-U133A	LSS TNNT1 SEC31B SBNO2 CHST8	3.54e-04	197	70	5	2554_DN
Drug	Benoxinate hydrochloride [5987-82-6]; Down 200; 11.6uM; PC3; HT_HG-U133A	JAK2 DZIP3 OTUD4 TAF1 DBP	3.54e-04	197	70	5	3996_DN
Drug	Hyoscyamine (L) [101-31-5]; Down 200; 13.8uM; PC3; HT_HG-U133A	PAFAH2 LSS TNFAIP3 TMEM63A STK25	3.62e-04	198	70	5	5099_DN
Drug	0198306-0000 [212631-61-3]; Up 200; 10uM; MCF7; HT_HG-U133A	TLN2 TNFAIP3 SBNO2 CHST8 TMEM63A	3.62e-04	198	70	5	7064_UP
Drug	Carbinoxamine maleate salt [3505-38-2]; Down 200; 9.8uM; MCF7; HT_HG-U133A	DLG3 TACC1 ABCD1 MKS1 STK25	3.62e-04	198	70	5	3466_DN
Drug	Clofazimine [2030-63-9]; Up 200; 8.4uM; MCF7; HT_HG-U133A	FRMD4A ABCD1 TAF1 TLR8 TMEM63A	3.70e-04	199	70	5	3239_UP
Drug	Gly-His-Lys acetate salt; Down 200; 1uM; PC3; HT_HG-U133A	SUPT7L PAFAH2 DZIP3 OTUD4 TMEM63A	3.70e-04	199	70	5	6560_DN
Drug	Tetrahydrozoline hydrochloride [522-48-5]; Down 200; 16.8uM; MCF7; HT_HG-U133A	FRMD4A DZIP3 TLN2 TACC1 TMEM63A	3.70e-04	199	70	5	6069_DN
Drug	Amoxicillin [26787-78-0]; Up 200; 11uM; PC3; HT_HG-U133A	PAFAH2 AMDHD2 DZIP3 TNFAIP3 TMEM63A	3.70e-04	199	70	5	6285_UP
Drug	carmustine; Down 200; 100uM; MCF7; HT_HG-U133A	SUPT7L DZIP3 ABCD1 TMEM63A STK25	3.70e-04	199	70	5	6888_DN
Drug	estradiol, USP; Up 200; 0.01uM; ssMCF7; HG-U133A	JAK2 TCHH RASSF1 ASPSCR1 TNFAIP3	3.70e-04	199	70	5	373_UP
Drug	prochlorperazine dimaleate salt; Down 200; 10uM; MCF7; HT_HG-U133A	TCHH UBTF TACC1 TAF1 SBNO2	3.70e-04	199	70	5	5575_DN
Drug	Methylatropine nitrate [52-88-0]; Down 200; 11uM; MCF7; HT_HG-U133A	TCHH DZIP3 ASPSCR1 SBNO2 CHST8	3.70e-04	199	70	5	6495_DN
Drug	DNA-PK Inhibitor III; Up 200; 1uM; PC3; HT_HG-U133A	JAK2 DZIP3 TLN2 CBFB CHST8	3.79e-04	200	70	5	7518_UP
Drug	Etanidazole [22668-01-5]; Down 200; 18.6uM; HL60; HT_HG-U133A	JAK2 UBTF TAF1 SBNO2 STK25	3.79e-04	200	70	5	2510_DN
Disease	beta-aminoisobutyric acid measurement	ARAP3 PAPSS1 CCDC26	2.61e-05	24	71	3	EFO_0010464
Disease	disease of cellular proliferation (implicated_via_orthology)	JAK1 JAK2	1.19e-04	7	71	2	DOID:14566 (implicated_via_orthology)
Disease	atrioventricular septal defect (implicated_via_orthology)	MKS1 DNAH11	1.19e-04	7	71	2	DOID:0050651 (implicated_via_orthology)
Disease	nasopharynx carcinoma (is_marker_for)	JAK2 TNFAIP3 SPEN	1.54e-04	43	71	3	DOID:9261 (is_marker_for)
Disease	Polycythemia Vera	JAK1 JAK2	1.58e-04	8	71	2	C0032463
Disease	Malignant neoplasm of breast	ARAP3 NRCAM SYNE1 SPATA18 LAMA2 CBFB KCNIP3 SPEN PKDREJ PGBD3	2.41e-04	1074	71	10	C0006142
Disease	Colorectal Carcinoma	ARAP3 ACACA NRCAM SYNE1 LAMA1 AMDHD2 DLG3 CHST8	2.80e-04	702	71	8	C0009402
Disease	Metastatic melanoma	PRKDC TAF1 ALPK2	3.03e-04	54	71	3	C0278883
Disease	glycerophosphorylcholine measurement	JAK1 DCLK2	3.10e-04	11	71	2	EFO_0020018
Disease	eosinophil percentage of leukocytes	JAK1 JAK2 PRKDC TNFAIP3 CCDC26 ALPK2 MKS1 SBNO2	4.20e-04	746	71	8	EFO_0007991
Disease	hematologic cancer (implicated_via_orthology)	JAK1 JAK2	4.38e-04	13	71	2	DOID:2531 (implicated_via_orthology)
Disease	heart disease (biomarker_via_orthology)	JAK2 CP	7.58e-04	17	71	2	DOID:114 (biomarker_via_orthology)
Disease	muscular dystrophy (is_implicated_in)	SYNE1 LAMA2	7.58e-04	17	71	2	DOID:9884 (is_implicated_in)
Disease	Leukemia, Myelocytic, Acute	JAK1 JAK2 CBFB SLX4	8.17e-04	173	71	4	C0023467
Disease	Hepatic Form of Wilson Disease	PPP3CB CP	1.52e-03	24	71	2	C1527352
Disease	Hepatolenticular Degeneration	PPP3CB CP	1.52e-03	24	71	2	C0019202
Disease	neutrophil percentage of granulocytes	JAK1 JAK2 PRKDC CCDC26	2.25e-03	228	71	4	EFO_0007994

Protein segments in the cluster

Peptide	Gene	Start	Entry
REEPEHDFSKISIVR	TACC1	136	O75410
PDEFFELTVDDVRRR	ASPSCR1	341	Q9BZE9
KRFFRELDDPVTSAR	ARAP3	981	Q8WWN8
RIFSPEHDIFRKSVR	ACADL	51	P28330
FSRHLPKDARADFRE	ALPK2	756	Q86TB3
PRREHRREAAFTLED	DNAH11	851	Q96DT5
RDKFEEDRIYRHLEP	ACACA	1361	Q13085
PRREEVKFFLRHEDS	PPP1R13B	71	Q96KQ4
KPDRERVEDFDHTSR	OTUD4	421	Q01804
DDPRKFALFERAERH	RASSF1	241	Q9NS23
DPTHFEKRFLKRIRD	JAK1	866	P23458
FEDRDPTQFEERHLK	JAK2	836	O60674
FEDVQRCHFKRPREL	ABCD1	426	P33897
TFRVPVERKAEEEHL	CP	791	P00450
KDPEEARFFVRSIEH	RAB3GAP2	1026	Q9H2M9
IRAEREELRNLHFFP	NRBP2	211	Q9NSY0
RELPSDERFTVDKDH	NRCAM	586	Q92823
IFRFVPRHEDELELE	MAPK8IP1	496	Q9UQF2
FDRERHKDPSPRDRD	SPATA18	106	Q8TC71
SIELEHFEERDKRPR	DCLK2	6	Q8N568
EIKYTGFRDRPHEER	CBFB	26	Q13951
SCLKDRHEFRFPEEE	IFNA7	51	P01567
REEAPREHVESFFQK	KCNIP2	221	Q9NS61
KRFPEHRAAEIRETL	LSS	546	P48449
DDPRVHRTVTREDFL	LAMA2	1316	P24043
LVVDPETDEHFKRLR	SLC9A3R2	226	Q15599
PRDARKETVESHFRD	TMEM63A	236	O94886
DEFFVRHPAVEDQRK	DZIP3	6	Q86Y13
ESAKDFIRHLLERDP	PNCK	241	Q6P2M8
AILRNPEFFEHRKEE	PAPSS1	336	O43252
PEFFEHRKEERCARQ	PAPSS1	341	O43252
ERSSRDREEKEAPFF	CCDC26	21	Q8TAB7
REKKFSVEVHDPRRA	FRMD4A	266	Q9P2Q2
PVDKFRGAHIRFEFR	DOCK4	476	Q8N1I0
AEEDFTREPRKIILH	DLG3	376	Q92796
ETFDPRRHRFSEEEL	DBP	221	Q10586
EKDEFRHTETQRPFV	FAM172BP	26	A6NC97
LREDAPAEHVERFFE	KCNIP3	206	Q9Y2W7
HTLDDIRRLDRFKEP	PPP3CB	216	P16298
IPFRRVEEGEKEFHV	PAFAH2	166	Q99487
DEKPVDFLEFRRRVV	PGBD3	506	Q8N328
PEGERVDFDDIHRKR	TNNT1	56	P13805
RRLKHFIGQREEFET	SYNE1	8101	Q8NF91
KRLYPSREEFREHLE	TAF1	1436	P21675
THPDERLTRKDFFFI	PKDREJ	1346	Q9NTG1
KRGDETREEIRHFTF	PSG9	126	Q00887
VEKRGDREEAHVPFF	LAMA1	2531	P25391
RRKFHRVTAEEAKEP	SBNO2	1111	Q9Y2G9
FEVDFRDPSLDLKHR	SEC31B	46	Q9NQW1
SFDLLPREFRLVEVH	SUPT7L	21	O94864
HSRVDPEELFTKLDR	STK25	11	O00506
FKRADPERLRHASEE	SLX4	216	Q8IY92
RDFPDDVISFIKRHS	SEMA3D	411	O95025
FERLVSAFRDKFEHP	CHST8	261	Q9H2A9
FREEIEDVEFPRKHL	SNX20	131	Q7Z614
RREFQELRHPVDEEK	TRIM74	176	Q86UV6
IRKRRSTDFEFDPHS	TLR8	451	Q9NR97
EFEEKLARFREEHPD	UBTFL6	166	P0CB48
EEKLARFREEHPDLV	UBTFL1	161	P0CB47
HAQPEEEERERRVFK	MKS1	271	Q9NXB0
DERIDEFHPKATRTL	SPEN	426	Q96T58
VNRDRGRFEDLKVHF	TNFAIP3	276	P21580
FSEIFRKEHPERFIE	TKTL2	351	Q9H0I9
RADHPFLFVIRKDDI	SERPINB7	356	O75635
FFLRIVHGRRSKPDE	ROBO2	91	Q9HCK4
ELVEDRFRKPHAFAV	RFX7	991	Q2KHR2
FRRREQRDPTVHDDV	PRKDC	2066	P78527
RKADRHREVDEDFPR	ZCCHC7	461	Q8N3Z6
HPDVSDEVRTRALRF	TLN2	2226	Q9Y4G6
RREFQELRHPVDEEK	TRIM73	176	Q86UV7
RKIRRRSPHEDTESF	SLC30A9	151	Q6PML9
EFERNLARFREDHPD	UBTF	171	P17480
SRLHIFDFDVDPLRR	SLC5A12	221	Q1EHB4
LHRQERDRKFLEEEP	TCHH	1636	Q07283
PEKLFFEERRVADER	AMDHD2	41	Q9Y303
RDKEPLQERFFRPHF	MYPN	1061	Q86TC9